SCHEMBL30795207

SCHEMBL30795207

CCn1c(=O)c(C(=O)NCc2ccc(F)cc2)c(C)c2ccc(C(F)(F)F)cc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.58
▸ MAPT P10636 3/20 0.51
▸ S1PR3 Q99500 2/20 0.47
▸ EGLN2 Q96KS0 1/20 0.46
▸ EGLN1 Q9GZT9 1/20 0.46
▸ EGLN3 Q9H6Z9 1/20 0.46
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ HTT P42858 2/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ PDE10A Q9Y233 1/20 0.44
▸ TSHR P16473 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ PTGER4 P35408 1/20 0.43
▸ LMNA P02545 2/20 0.43
▸ TP53 P04637 1/20 0.43
▸ NPC1 O15118 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL713970 1.00 L3MBTL1 (0.58) L3MBTL1MAPTS1PR3EGLN2EGLN1
SCHEMBL716049 0.90 S1PR3 (0.50) L3MBTL1MAPTS1PR3EGLN2EGLN1
SCHEMBL30795805 0.90 S1PR3 (0.50) L3MBTL1MAPTS1PR3EGLN2EGLN1
SCHEMBL28806 0.89 L3MBTL1 (0.46) L3MBTL1MAPTS1PR3EGLN2EGLN1
SCHEMBL30795356 0.89 L3MBTL1 (0.46) L3MBTL1MAPTS1PR3EGLN2EGLN1
SCHEMBL30795584 0.88 MEN1 (0.57) L3MBTL1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL714808 0.88 MEN1 (0.57) L3MBTL1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL30795738 0.82 S1PR3 (0.47) MAPTS1PR3MEN1KMT2AHTT
SCHEMBL715295 0.82 S1PR3 (0.47) MAPTS1PR3MEN1KMT2AHTT
SCHEMBL29573 0.81 MEN1 (0.46) L3MBTL1MAPTS1PR3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 — — EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 — — EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 — — WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 — — WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 — — WO disclosed
Send feedback